Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,066,349 papers from all fields of science
Search
Sign In
Create Free Account
SOM-230
Known as:
SOM 230
, SOM230
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
pasireotide
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.
L. Kvols
,
K. Oberg
,
+8 authors
B. Wiedenmann
Endocrine-Related Cancer
2012
Corpus ID: 25401312
Pasireotide (SOM230) is a novel multireceptor-targeted somatostatin (sst) analog with high binding affinity for sst receptor…
Expand
Review
2010
Review
2010
Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
K. Oberg
,
J. Reubi
,
D. Kwekkeboom
,
E. Krenning
Gastroenterology
2010
Corpus ID: 27920594
The incidence and prevalence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have increased in the past 20 years. GEP…
Expand
Review
2009
Review
2009
Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours
I. Modlin
,
M. Pavel
,
M. Kidd
,
B. Gustafsson
Alimentary Pharmacology and Therapeutics
2009
Corpus ID: 205245600
Background The discovery of somatostatin (SST) and the synthesis of a variety of analogues constituted a major therapeutic…
Expand
Highly Cited
2009
Highly Cited
2009
Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.
M. Boscaro
,
W. Ludlam
,
+15 authors
J. Bertherat
Journal of Clinical Endocrinology and Metabolism
2009
Corpus ID: 207077678
CONTEXT There is currently no medical therapy for Cushing's disease that targets the pituitary adenoma. Availability of such a…
Expand
Review
2008
Review
2008
Pasireotide (SOM230): Development, mechanism of action and potential applications
H. Schmid
Molecular and Cellular Endocrinology
2008
Corpus ID: 8975340
Highly Cited
2006
Highly Cited
2006
The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas.
D. Batista
,
Xun Zhang
,
+7 authors
A. Klibanski
Journal of Clinical Endocrinology and Metabolism
2006
Corpus ID: 45377762
CONTEXT There is no tumor-directed medical therapy available for Cushing's disease. OBJECTIVE The objective was to determine…
Expand
Highly Cited
2005
Highly Cited
2005
Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells.
J. van der Hoek
,
M. Waaijers
,
+10 authors
L. Hofland
American Journal of Physiology. Endocrinology and…
2005
Corpus ID: 6744306
In a series of human corticotroph adenomas, we recently found predominant mRNA expression of somatostatin (SS) receptor subtype 5…
Expand
Highly Cited
2004
Highly Cited
2004
Functional Activity of the Multiligand Analog SOM230 at Human Recombinant Somatostatin Receptor Subtypes Supports Its Usefulness in Neuroendocrine Tumors
H. Schmid
,
P. Schoeffter
Neuroendocrinology
2004
Corpus ID: 21550450
Functional gastroenteropancreatic tumors express all 5 somatostatin receptor subtypes (sst) in different quantities. Octreotide…
Expand
Highly Cited
2004
Highly Cited
2004
A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients.
J. van der Hoek
,
W. D. de Herder
,
+10 authors
S. Lamberts
Journal of Clinical Endocrinology and Metabolism
2004
Corpus ID: 24535175
Treatment with the somatostatin receptor (sst) subtype 2 predominant analogs octreotide and lanreotide induces clinical and…
Expand
Highly Cited
2002
Highly Cited
2002
SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.
C. Bruns
,
I. Lewis
,
U. Briner
,
G. Meno-Tetang
,
G. Weckbecker
European Journal of Endocrinology
2002
Corpus ID: 29075948
OBJECTIVE The aim of the present study was to identify a small, metabolically stable somatotropin release inhibiting factor (SRIF…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE